Intelligent Bio Solutions Inc. (INBS) vs Liminatus Pharma, Inc. Class A Common Stock (LIMN)

A side-by-side comparison of Intelligent Bio Solutions Inc. and Liminatus Pharma, Inc. Class A Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Intelligent Bio Solutions Inc. logo
INBS
Intelligent Bio Solutions Inc.
$5M
$1.58HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Liminatus Pharma, Inc. Class A Common Stock logo
LIMN
Liminatus Pharma, Inc. Class A Common Stock
$5M
$3.88HealthcareDelayed quote: Oct 6, 2026, 11:26 AM EDT

Total return — INBS vs LIMN

growth of $100 · dividends reinvested · last 1y
INBS -87.1% (-87.1%/yr)LIMN -98.4% (-98.4%/yr)INBS compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $1002026$13$2
INBS LIMN

INBS vs LIMN: by the numbers

  • •INBS is the larger company ($5M vs $5M market cap).
  • •Both run net losses; LIMN's is the smaller (0.00% vs -294.91% net margin).

Metrics side by side

Valuation

MetricINBSLIMN
P/S ratio1.24N/A
P/B ratio0.9517.34

Profitability

MetricINBSLIMN
Gross margin48.63%0.00%
Operating margin-305.03%0.00%
Net margin-294.91%0.00%
ROE-225.57%-4165.92%
ROIC-179.58%-225.12%

Growth (annualized)

MetricINBSLIMN
Revenue CAGR (5Y)19.95%N/A
Total return CAGR (5Y)-80.26%N/A

Go deeper

Full INBS analysisFull LIMN analysisInteractive comparison tool

Dig into the metrics

Intelligent Bio Solutions ROELiminatus Pharma, Inc. Class A Common Stock ROEIntelligent Bio Solutions operating marginLiminatus Pharma, Inc. Class A Common Stock operating marginIntelligent Bio Solutions revenue growthLiminatus Pharma, Inc. Class A Common Stock revenue growthIntelligent Bio Solutions free cash flowLiminatus Pharma, Inc. Class A Common Stock free cash flow

Intelligent Bio Solutions & Liminatus Pharma, Inc. Class A Common Stock appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.